Diaceutics (LON:DXRX) Hits New 12-Month High – Should You Buy?

Diaceutics PLC (LON:DXRX) hit a new 52-week high on Thursday . The stock traded as high as GBX 136 ($1.70) and last traded at GBX 136 ($1.70), with a volume of 101158 shares traded. The stock had previously closed at GBX 125.50 ($1.57).

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on DXRX shares. Canaccord Genuity Group reiterated a “buy” rating and set a GBX 160 ($2.00) price objective on shares of Diaceutics in a research report on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($2.00) price target on shares of Diaceutics in a research report on Tuesday, December 17th.

Diaceutics Stock Up 8.4 %

The stock has a market cap of £114.88 million, a price-to-earnings ratio of -4,533.33 and a beta of 0.58. The company has a debt-to-equity ratio of 2.93, a quick ratio of 9.92 and a current ratio of 4.85. The business’s 50 day moving average is GBX 120.33 and its 200 day moving average is GBX 125.86.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.